Details of the Drug Combinations

General Information of This Drug (ID: DMLHEU7)

Drug Name
Ridaforolimus   DMLHEU7
Synonyms Deforolimus; AP 23573; MK 8669; AP-23573; MK-8669; AP23573, MK-8669, Ridaforolimus, Deforolimus
Indication
Disease Entry ICD 11 Status REF
Sarcoma 2A60-2C35 Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

556 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
10-hydroxycamptothecin + Ridaforolimus DCC7TWY 10-hydroxycamptothecin Breast and ovarian cancer syndrome (Cell Line: UWB1289) [2]
10-hydroxycamptothecin + Ridaforolimus DC1RUS2 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH2122) [3]
10-hydroxycamptothecin + Ridaforolimus DCT9ZFR 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH520) [3]
10-hydroxycamptothecin + Ridaforolimus DC0L68I 10-hydroxycamptothecin Adenocarcinoma (Cell Line: HT29) [3]
10-hydroxycamptothecin + Ridaforolimus DC4X7ZW 10-hydroxycamptothecin Amelanotic melanoma (Cell Line: A2058) [3]
10-hydroxycamptothecin + Ridaforolimus DCJ4JQG 10-hydroxycamptothecin Mesothelioma (Cell Line: MSTO) [3]
10-hydroxycamptothecin + Ridaforolimus DCZ1UER 10-hydroxycamptothecin Non small cell carcinoma (Cell Line: SKMES1) [3]
10-hydroxycamptothecin + Ridaforolimus DCYP0SO 10-hydroxycamptothecin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
10-hydroxycamptothecin + Ridaforolimus DCKTR1W 10-hydroxycamptothecin Prostate carcinoma (Cell Line: LNCAP) [3]
Bafilomycin A1 + Ridaforolimus DCM8MFA Bafilomycin A1 Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Bortezomib + Ridaforolimus DCHNK71 Bortezomib Adenocarcinoma (Cell Line: NCIH2122) [4]
Bortezomib + Ridaforolimus DC0JJED Bortezomib Adenocarcinoma (Cell Line: COLO320DM) [4]
Bortezomib + Ridaforolimus DCLGER4 Bortezomib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Bortezomib + Ridaforolimus DCPHVWI Bortezomib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Bortezomib + Ridaforolimus DCU6ET4 Bortezomib Breast carcinoma (Cell Line: ZR751) [2]
Bortezomib + Ridaforolimus DCP4R3D Bortezomib Breast carcinoma (Cell Line: KPL1) [2]
Dasatinib + Ridaforolimus DCVT8JT Dasatinib Adenocarcinoma (Cell Line: CAOV3) [4]
Dasatinib + Ridaforolimus DC5RNED Dasatinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Dasatinib + Ridaforolimus DC6XTB6 Dasatinib Adenocarcinoma (Cell Line: NCIH1650) [4]
Dasatinib + Ridaforolimus DCTSFQZ Dasatinib Adenocarcinoma (Cell Line: NCIH23) [4]
Dasatinib + Ridaforolimus DCNQQZ8 Dasatinib Adenocarcinoma (Cell Line: NCIH520) [4]
Dasatinib + Ridaforolimus DC6RJSL Dasatinib Adenocarcinoma (Cell Line: DLD1) [4]
Dasatinib + Ridaforolimus DCU1O9M Dasatinib Adenocarcinoma (Cell Line: HT29) [4]
Dasatinib + Ridaforolimus DCA0YNT Dasatinib Adenocarcinoma (Cell Line: SW-620) [4]
Dasatinib + Ridaforolimus DCB3VLK Dasatinib Amelanotic melanoma (Cell Line: A2058) [4]
Dasatinib + Ridaforolimus DCW5L9G Dasatinib Germ cell tumour (Cell Line: PA1) [4]
Dasatinib + Ridaforolimus DCPOD3J Dasatinib Malignant melanoma (Cell Line: A375) [4]
Dasatinib + Ridaforolimus DC03VM6 Dasatinib Mesothelioma (Cell Line: MSTO) [4]
Dasatinib + Ridaforolimus DCZGIYU Dasatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Dasatinib + Ridaforolimus DC9JV3I Dasatinib Prostate carcinoma (Cell Line: LNCAP) [4]
Dasatinib + Ridaforolimus DCYHA38 Dasatinib Breast carcinoma (Cell Line: KPL1) [2]
Dasatinib + Ridaforolimus DCZJH7D Dasatinib Breast carcinoma (Cell Line: OCUBM) [2]
Dasatinib + Ridaforolimus DC3OG0W Dasatinib Carcinoma (Cell Line: OV90) [2]
Dasatinib + Ridaforolimus DCK9T9B Dasatinib Carcinoma (Cell Line: EFM192B) [2]
Dasatinib + Ridaforolimus DCHBIEM Dasatinib Carcinoma (Cell Line: MDAMB436) [2]
Dasatinib + Ridaforolimus DCIJZJ6 Dasatinib Colon carcinoma (Cell Line: RKO) [2]
Dasatinib + Ridaforolimus DCBWQPK Dasatinib Invasive ductal carcinoma (Cell Line: T-47D) [2]
Dasatinib + Ridaforolimus DCEDLL2 Dasatinib Rectal adenocarcinoma (Cell Line: SW837) [2]
Dexamethasone + Ridaforolimus DCIIVTM Dexamethasone Breast carcinoma (Cell Line: KPL1) [2]
Dexamethasone + Ridaforolimus DC41P8S Dexamethasone Adenocarcinoma (Cell Line: CAOV3) [3]
Dexamethasone + Ridaforolimus DCXZFEJ Dexamethasone Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Doxorubicin + Ridaforolimus DC9VTGH Doxorubicin Adenocarcinoma (Cell Line: NCIH1650) [4]
Doxorubicin + Ridaforolimus DCGXUBO Doxorubicin Adenocarcinoma (Cell Line: NCIH2122) [4]
Doxorubicin + Ridaforolimus DCBM264 Doxorubicin Adenocarcinoma (Cell Line: COLO320DM) [4]
Doxorubicin + Ridaforolimus DCP9YJC Doxorubicin Adenocarcinoma (Cell Line: DLD1) [4]
Doxorubicin + Ridaforolimus DC089IJ Doxorubicin Adenocarcinoma (Cell Line: HCT116) [4]
Doxorubicin + Ridaforolimus DC48ALA Doxorubicin Adenocarcinoma (Cell Line: HT29) [4]
Doxorubicin + Ridaforolimus DC0DV2Y Doxorubicin Adenocarcinoma (Cell Line: SW-620) [4]
Doxorubicin + Ridaforolimus DCM3069 Doxorubicin Amelanotic melanoma (Cell Line: A2058) [4]
Doxorubicin + Ridaforolimus DC7AQN9 Doxorubicin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Doxorubicin + Ridaforolimus DCKBHR7 Doxorubicin Germ cell tumour (Cell Line: PA1) [4]
Doxorubicin + Ridaforolimus DCUJSE8 Doxorubicin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Doxorubicin + Ridaforolimus DCY8S0H Doxorubicin Malignant melanoma (Cell Line: SKMEL30) [4]
Doxorubicin + Ridaforolimus DC5PWCB Doxorubicin Mesothelioma (Cell Line: MSTO) [4]
Doxorubicin + Ridaforolimus DC20GV1 Doxorubicin Non small cell carcinoma (Cell Line: SKMES1) [4]
Doxorubicin + Ridaforolimus DCGK93L Doxorubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Doxorubicin + Ridaforolimus DCWB7QG Doxorubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Doxorubicin + Ridaforolimus DC45DWA Doxorubicin Prostate carcinoma (Cell Line: VCAP) [4]
Doxorubicin + Ridaforolimus DC4L0BQ Doxorubicin Prostate carcinoma (Cell Line: LNCAP) [4]
Doxorubicin + Ridaforolimus DCDGCGX Doxorubicin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
Doxorubicin + Ridaforolimus DC075OH Doxorubicin Breast carcinoma (Cell Line: ZR751) [2]
Doxorubicin + Ridaforolimus DCUKI2Z Doxorubicin Breast carcinoma (Cell Line: OCUBM) [2]
Doxorubicin + Ridaforolimus DC5NT18 Doxorubicin Carcinoma (Cell Line: EFM192B) [2]
Doxorubicin + Ridaforolimus DCTTROD Doxorubicin Colon adenocarcinoma (Cell Line: LOVO) [2]
Doxorubicin + Ridaforolimus DCRYRQ4 Doxorubicin Colon carcinoma (Cell Line: RKO) [2]
Doxorubicin + Ridaforolimus DCNMJDD Doxorubicin Invasive ductal carcinoma (Cell Line: T-47D) [2]
Erlotinib + Ridaforolimus DCWH7NK Erlotinib Adenocarcinoma (Cell Line: OVCAR3) [4]
Erlotinib + Ridaforolimus DCR179M Erlotinib Adenocarcinoma (Cell Line: CAOV3) [4]
Erlotinib + Ridaforolimus DCV6JQ5 Erlotinib Adenocarcinoma (Cell Line: A427) [4]
Erlotinib + Ridaforolimus DCLTVXF Erlotinib Adenocarcinoma (Cell Line: NCIH1650) [4]
Erlotinib + Ridaforolimus DCA65YB Erlotinib Adenocarcinoma (Cell Line: NCIH2122) [4]
Erlotinib + Ridaforolimus DCC1QVD Erlotinib Adenocarcinoma (Cell Line: NCIH23) [4]
Erlotinib + Ridaforolimus DCJMJV6 Erlotinib Adenocarcinoma (Cell Line: NCIH520) [4]
Erlotinib + Ridaforolimus DC8N6CQ Erlotinib Adenocarcinoma (Cell Line: COLO320DM) [4]
Erlotinib + Ridaforolimus DCFRRB8 Erlotinib Adenocarcinoma (Cell Line: DLD1) [4]
Erlotinib + Ridaforolimus DCW7RFA Erlotinib Adenocarcinoma (Cell Line: HT29) [4]
Erlotinib + Ridaforolimus DCEAV2S Erlotinib Adenocarcinoma (Cell Line: SW-620) [4]
Erlotinib + Ridaforolimus DCB7UL1 Erlotinib Amelanotic melanoma (Cell Line: A2058) [4]
Erlotinib + Ridaforolimus DCN4F3B Erlotinib Germ cell tumour (Cell Line: PA1) [4]
Erlotinib + Ridaforolimus DCMY13N Erlotinib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Erlotinib + Ridaforolimus DC1W58Z Erlotinib Malignant melanoma (Cell Line: HT144) [4]
Erlotinib + Ridaforolimus DC0K92Q Erlotinib Malignant melanoma (Cell Line: RPMI7951) [4]
Erlotinib + Ridaforolimus DCFNJJW Erlotinib Malignant melanoma (Cell Line: SKMEL30) [4]
Erlotinib + Ridaforolimus DCKGOOX Erlotinib Malignant melanoma (Cell Line: UACC62) [4]
Erlotinib + Ridaforolimus DCL77IM Erlotinib Malignant melanoma (Cell Line: A375) [4]
Erlotinib + Ridaforolimus DC28KEE Erlotinib Mesothelioma (Cell Line: MSTO) [4]
Erlotinib + Ridaforolimus DCDLBFY Erlotinib Non small cell carcinoma (Cell Line: SKMES1) [4]
Erlotinib + Ridaforolimus DCIP0BL Erlotinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Erlotinib + Ridaforolimus DCBIK1Y Erlotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Erlotinib + Ridaforolimus DC1OSCM Erlotinib Prostate carcinoma (Cell Line: LNCAP) [4]
Erlotinib + Ridaforolimus DCHXF6G Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [2]
Erlotinib + Ridaforolimus DCTO9BJ Erlotinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
Erlotinib + Ridaforolimus DCR9IU3 Erlotinib Breast carcinoma (Cell Line: KPL1) [2]
Erlotinib + Ridaforolimus DCS17XZ Erlotinib Carcinoma (Cell Line: OV90) [2]
Erlotinib + Ridaforolimus DCKUQFO Erlotinib Carcinoma (Cell Line: EFM192B) [2]
Erlotinib + Ridaforolimus DC8Q3MD Erlotinib Colon adenocarcinoma (Cell Line: LOVO) [2]
Erlotinib + Ridaforolimus DC9YWTC Erlotinib Invasive ductal carcinoma (Cell Line: T-47D) [2]
Erlotinib + Ridaforolimus DCVDVPX Erlotinib Rectal adenocarcinoma (Cell Line: SW837) [2]
Estramustine + Ridaforolimus DCCVDSU Estramustine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Estramustine + Ridaforolimus DCCAMEO Estramustine Breast carcinoma (Cell Line: KPL1) [2]
Estramustine + Ridaforolimus DC3NB9F Estramustine Amelanotic melanoma (Cell Line: A2058) [3]
Estramustine + Ridaforolimus DC01IYE Estramustine Malignant melanoma (Cell Line: RPMI7951) [3]
Estramustine + Ridaforolimus DCBQ6A5 Estramustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Estramustine + Ridaforolimus DCZ9BR2 Estramustine Prostate carcinoma (Cell Line: LNCAP) [3]
Etoposide + Ridaforolimus DCUX6G9 Etoposide Adenocarcinoma (Cell Line: CAOV3) [4]
Etoposide + Ridaforolimus DC4Y9Z8 Etoposide Adenocarcinoma (Cell Line: NCIH1650) [4]
Etoposide + Ridaforolimus DCF0E3Z Etoposide Adenocarcinoma (Cell Line: NCIH2122) [4]
Etoposide + Ridaforolimus DCB8OFC Etoposide Adenocarcinoma (Cell Line: COLO320DM) [4]
Etoposide + Ridaforolimus DCX1YQ3 Etoposide Adenocarcinoma (Cell Line: DLD1) [4]
Etoposide + Ridaforolimus DCEHM8Z Etoposide Adenocarcinoma (Cell Line: HCT116) [4]
Etoposide + Ridaforolimus DC8JKKI Etoposide Adenocarcinoma (Cell Line: HT29) [4]
Etoposide + Ridaforolimus DC06FJZ Etoposide Amelanotic melanoma (Cell Line: A2058) [4]
Etoposide + Ridaforolimus DCCKZKO Etoposide Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Etoposide + Ridaforolimus DCU5033 Etoposide Malignant melanoma (Cell Line: RPMI7951) [4]
Etoposide + Ridaforolimus DC1XQKW Etoposide Malignant melanoma (Cell Line: UACC62) [4]
Etoposide + Ridaforolimus DCGDTSF Etoposide Mesothelioma (Cell Line: MSTO) [4]
Etoposide + Ridaforolimus DCKZD5R Etoposide Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Etoposide + Ridaforolimus DC6I0CI Etoposide Prostate carcinoma (Cell Line: LNCAP) [4]
Etoposide + Ridaforolimus DCI1W22 Etoposide Prostate carcinoma (Cell Line: VCAP) [4]
Etoposide + Ridaforolimus DCHQFPY Etoposide Breast and ovarian cancer syndrome (Cell Line: UWB1289) [2]
Etoposide + Ridaforolimus DCM531A Etoposide Breast carcinoma (Cell Line: KPL1) [2]
Etoposide + Ridaforolimus DC58AVR Etoposide Breast carcinoma (Cell Line: OCUBM) [2]
Etoposide + Ridaforolimus DCA806E Etoposide Carcinoma (Cell Line: EFM192B) [2]
Etoposide + Ridaforolimus DC16211 Etoposide Colon adenocarcinoma (Cell Line: LOVO) [2]
Etoposide + Ridaforolimus DCMOAP9 Etoposide Colon carcinoma (Cell Line: RKO) [2]
Etoposide + Ridaforolimus DCKMPP2 Etoposide Invasive ductal carcinoma (Cell Line: T-47D) [2]
Evacetrapib + Ridaforolimus DCEF4AL Evacetrapib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Fluorouracil + Ridaforolimus DCOW8Q8 Fluorouracil Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
Fluorouracil + Ridaforolimus DCBAU8D Fluorouracil Breast carcinoma (Cell Line: KPL1) [2]
Fluorouracil + Ridaforolimus DCINCZD Fluorouracil Carcinoma (Cell Line: MDAMB436) [2]
Fluorouracil + Ridaforolimus DCL2A35 Fluorouracil Rectal adenocarcinoma (Cell Line: SW837) [2]
Fluorouracil + Ridaforolimus DC5Z402 Fluorouracil Adenocarcinoma (Cell Line: CAOV3) [3]
Fluorouracil + Ridaforolimus DCBTUEN Fluorouracil Adenocarcinoma (Cell Line: A427) [3]
Fluorouracil + Ridaforolimus DC7P7DK Fluorouracil Adenocarcinoma (Cell Line: NCIH1650) [3]
Fluorouracil + Ridaforolimus DCHKCZU Fluorouracil Adenocarcinoma (Cell Line: NCIH23) [3]
Fluorouracil + Ridaforolimus DCMAB1Z Fluorouracil Adenocarcinoma (Cell Line: NCIH520) [3]
Fluorouracil + Ridaforolimus DC9D2SW Fluorouracil Adenocarcinoma (Cell Line: DLD1) [3]
Fluorouracil + Ridaforolimus DCHY948 Fluorouracil Adenocarcinoma (Cell Line: HT29) [3]
Fluorouracil + Ridaforolimus DCMWW4Q Fluorouracil Germ cell tumour (Cell Line: PA1) [3]
Fluorouracil + Ridaforolimus DCGRAST Fluorouracil Malignant melanoma (Cell Line: A375) [3]
Fluorouracil + Ridaforolimus DCP7FYQ Fluorouracil Malignant melanoma (Cell Line: RPMI7951) [3]
Fluorouracil + Ridaforolimus DCS95YE Fluorouracil Non small cell carcinoma (Cell Line: SKMES1) [3]
Fluorouracil + Ridaforolimus DCD7TJ8 Fluorouracil Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Fluorouracil + Ridaforolimus DCDAQ3J Fluorouracil Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Gemcitabine + Ridaforolimus DC5EGK9 Gemcitabine Adenocarcinoma (Cell Line: NCIH2122) [4]
Gemcitabine + Ridaforolimus DCQ2RYH Gemcitabine Adenocarcinoma (Cell Line: NCIH520) [4]
Gemcitabine + Ridaforolimus DCZXMQE Gemcitabine Adenocarcinoma (Cell Line: COLO320DM) [4]
Gemcitabine + Ridaforolimus DC7O8DW Gemcitabine Adenocarcinoma (Cell Line: HT29) [4]
Gemcitabine + Ridaforolimus DCTN1R0 Gemcitabine Amelanotic melanoma (Cell Line: A2058) [4]
Gemcitabine + Ridaforolimus DC3EAKD Gemcitabine Germ cell tumour (Cell Line: PA1) [4]
Gemcitabine + Ridaforolimus DCAV6P0 Gemcitabine Malignant melanoma (Cell Line: A375) [4]
Gemcitabine + Ridaforolimus DCGURKJ Gemcitabine Malignant melanoma (Cell Line: RPMI7951) [4]
Gemcitabine + Ridaforolimus DCEK73S Gemcitabine Prostate carcinoma (Cell Line: VCAP) [4]
Gemcitabine + Ridaforolimus DC4W6G2 Gemcitabine Breast carcinoma (Cell Line: OCUBM) [2]
Gemcitabine + Ridaforolimus DCMXAYU Gemcitabine Invasive ductal carcinoma (Cell Line: T-47D) [2]
GSK525762 + Ridaforolimus DC94LVZ GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [2]
GSK525762 + Ridaforolimus DCTE3SH GSK525762 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
GSK525762 + Ridaforolimus DC15WQT GSK525762 Breast carcinoma (Cell Line: KPL1) [2]
GSK525762 + Ridaforolimus DCYWRG4 GSK525762 Carcinoma (Cell Line: MDAMB436) [2]
GSK525762 + Ridaforolimus DC2BSLI GSK525762 Adenocarcinoma (Cell Line: CAOV3) [3]
GSK525762 + Ridaforolimus DCXO43Z GSK525762 Adenocarcinoma (Cell Line: NCIH1650) [3]
GSK525762 + Ridaforolimus DC3OGA9 GSK525762 Adenocarcinoma (Cell Line: NCIH2122) [3]
GSK525762 + Ridaforolimus DC4ER79 GSK525762 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
GSK525762 + Ridaforolimus DCKZ18U GSK525762 Prostate carcinoma (Cell Line: LNCAP) [3]
Idarubicin + Ridaforolimus DC8H1YH Idarubicin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
Idarubicin + Ridaforolimus DC5RM9J Idarubicin Adenocarcinoma (Cell Line: A427) [3]
Idarubicin + Ridaforolimus DCSWFFQ Idarubicin Adenocarcinoma (Cell Line: COLO320DM) [3]
Idarubicin + Ridaforolimus DCFCXPK Idarubicin Amelanotic melanoma (Cell Line: A2058) [3]
Idarubicin + Ridaforolimus DCZ8RF3 Idarubicin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Idarubicin + Ridaforolimus DC09LTY Idarubicin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Lapatinib + Ridaforolimus DCWAAUK Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [2]
Lapatinib + Ridaforolimus DC8HVA8 Lapatinib Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
Lapatinib + Ridaforolimus DCY0OS1 Lapatinib Breast carcinoma (Cell Line: KPL1) [2]
Lapatinib + Ridaforolimus DCMP7O2 Lapatinib Breast carcinoma (Cell Line: OCUBM) [2]
Lapatinib + Ridaforolimus DCNGB7O Lapatinib Carcinoma (Cell Line: EFM192B) [2]
Lapatinib + Ridaforolimus DCNJLIT Lapatinib Carcinoma (Cell Line: MDAMB436) [2]
Lapatinib + Ridaforolimus DCSFJHE Lapatinib Colon carcinoma (Cell Line: RKO) [2]
Lapatinib + Ridaforolimus DC67AO2 Lapatinib Invasive ductal carcinoma (Cell Line: T-47D) [2]
Lapatinib + Ridaforolimus DCVLOIM Lapatinib Rectal adenocarcinoma (Cell Line: SW837) [2]
Lapatinib + Ridaforolimus DCR7RQ8 Lapatinib Adenocarcinoma (Cell Line: CAOV3) [3]
Lapatinib + Ridaforolimus DCXVROI Lapatinib Adenocarcinoma (Cell Line: NCIH1650) [3]
Lapatinib + Ridaforolimus DC4XGCD Lapatinib Adenocarcinoma (Cell Line: NCIH2122) [3]
Lapatinib + Ridaforolimus DCP7287 Lapatinib Adenocarcinoma (Cell Line: NCIH23) [3]
Lapatinib + Ridaforolimus DC0CIAD Lapatinib Adenocarcinoma (Cell Line: NCIH520) [3]
Lapatinib + Ridaforolimus DCWC6LW Lapatinib Adenocarcinoma (Cell Line: COLO320DM) [3]
Lapatinib + Ridaforolimus DC5O3XS Lapatinib Adenocarcinoma (Cell Line: DLD1) [3]
Lapatinib + Ridaforolimus DC66JPI Lapatinib Adenocarcinoma (Cell Line: HCT116) [3]
Lapatinib + Ridaforolimus DCNWRA3 Lapatinib Amelanotic melanoma (Cell Line: A2058) [3]
Lapatinib + Ridaforolimus DC8NE1P Lapatinib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Lapatinib + Ridaforolimus DC60AWK Lapatinib Malignant melanoma (Cell Line: RPMI7951) [3]
Lapatinib + Ridaforolimus DCW8KCC Lapatinib Malignant melanoma (Cell Line: SKMEL30) [3]
Lapatinib + Ridaforolimus DCIO4YZ Lapatinib Malignant melanoma (Cell Line: UACC62) [3]
Lapatinib + Ridaforolimus DCBE837 Lapatinib Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Lapatinib + Ridaforolimus DCNQ2OQ Lapatinib Prostate carcinoma (Cell Line: LNCAP) [3]
Lomustine + Ridaforolimus DCJ5MMV Lomustine Breast carcinoma (Cell Line: KPL1) [2]
Lomustine + Ridaforolimus DCO3F1D Lomustine Breast carcinoma (Cell Line: OCUBM) [2]
Lomustine + Ridaforolimus DCPBPVS Lomustine Colon carcinoma (Cell Line: RKO) [2]
Lomustine + Ridaforolimus DCIQZ2T Lomustine Adenocarcinoma (Cell Line: CAOV3) [3]
Lomustine + Ridaforolimus DCLVZUS Lomustine Adenocarcinoma (Cell Line: NCIH1650) [3]
Lomustine + Ridaforolimus DCB4U8H Lomustine Adenocarcinoma (Cell Line: HCT116) [3]
Lomustine + Ridaforolimus DC8NI0N Lomustine Malignant melanoma (Cell Line: RPMI7951) [3]
Lomustine + Ridaforolimus DCGZL57 Lomustine Malignant melanoma (Cell Line: UACC62) [3]
Lomustine + Ridaforolimus DC9OWTB Lomustine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Lomustine + Ridaforolimus DCGTO8K Lomustine Prostate carcinoma (Cell Line: LNCAP) [3]
Lomustine + Ridaforolimus DCIYAZO Lomustine Prostate carcinoma (Cell Line: VCAP) [3]
Metformin + Ridaforolimus DC2XSPE Metformin Adenocarcinoma (Cell Line: NCIH2122) [4]
Metformin + Ridaforolimus DCEZXSM Metformin Adenocarcinoma (Cell Line: HT29) [4]
Metformin + Ridaforolimus DCTVLJB Metformin Breast carcinoma (Cell Line: KPL1) [2]
Methotrexate + Ridaforolimus DCS67P8 Methotrexate Adenocarcinoma (Cell Line: CAOV3) [4]
Methotrexate + Ridaforolimus DCWYVAB Methotrexate Adenocarcinoma (Cell Line: NCIH2122) [4]
Methotrexate + Ridaforolimus DCZPHQM Methotrexate Adenocarcinoma (Cell Line: NCIH23) [4]
Methotrexate + Ridaforolimus DCGLFI4 Methotrexate Adenocarcinoma (Cell Line: DLD1) [4]
Methotrexate + Ridaforolimus DC8EQVW Methotrexate Adenocarcinoma (Cell Line: SW-620) [4]
Methotrexate + Ridaforolimus DCOUCLT Methotrexate Amelanotic melanoma (Cell Line: A2058) [4]
Methotrexate + Ridaforolimus DC6LZ9N Methotrexate Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Methotrexate + Ridaforolimus DCN9KW5 Methotrexate Malignant melanoma (Cell Line: A375) [4]
Methotrexate + Ridaforolimus DCORPAT Methotrexate Mesothelioma (Cell Line: MSTO) [4]
Methotrexate + Ridaforolimus DCLBVE5 Methotrexate Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
Methotrexate + Ridaforolimus DCX9LJX Methotrexate Colon carcinoma (Cell Line: RKO) [2]
Methotrexate + Ridaforolimus DCPILFH Methotrexate Rectal adenocarcinoma (Cell Line: SW837) [2]
Mitomycin + Ridaforolimus DCZI8HN Mitomycin Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Mitomycin + Ridaforolimus DCK57KE Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289) [2]
Mitomycin + Ridaforolimus DCLB655 Mitomycin Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
Mitomycin + Ridaforolimus DCALZ0F Mitomycin Breast carcinoma (Cell Line: OCUBM) [2]
Mitomycin + Ridaforolimus DCMWDDH Mitomycin Carcinoma (Cell Line: EFM192B) [2]
Mitomycin + Ridaforolimus DC4K55M Mitomycin Colon adenocarcinoma (Cell Line: LOVO) [2]
Mitomycin + Ridaforolimus DCROOK2 Mitomycin Invasive ductal carcinoma (Cell Line: T-47D) [2]
Mitomycin + Ridaforolimus DC16S4W Mitomycin Rectal adenocarcinoma (Cell Line: SW837) [2]
Mitomycin + Ridaforolimus DCE0MFI Mitomycin Adenocarcinoma (Cell Line: CAOV3) [3]
Mitomycin + Ridaforolimus DC4W5KV Mitomycin Adenocarcinoma (Cell Line: A427) [3]
Mitomycin + Ridaforolimus DC4KMN2 Mitomycin Adenocarcinoma (Cell Line: NCIH2122) [3]
Mitomycin + Ridaforolimus DC8ZW1T Mitomycin Adenocarcinoma (Cell Line: NCIH23) [3]
Mitomycin + Ridaforolimus DCUGYGG Mitomycin Adenocarcinoma (Cell Line: NCIH520) [3]
Mitomycin + Ridaforolimus DCTBOPL Mitomycin Adenocarcinoma (Cell Line: COLO320DM) [3]
Mitomycin + Ridaforolimus DCLKW9U Mitomycin Adenocarcinoma (Cell Line: HT29) [3]
Mitomycin + Ridaforolimus DC00GL3 Mitomycin Adenocarcinoma (Cell Line: SW-620) [3]
Mitomycin + Ridaforolimus DCXKF2J Mitomycin Amelanotic melanoma (Cell Line: A2058) [3]
Mitomycin + Ridaforolimus DCRWUP5 Mitomycin Germ cell tumour (Cell Line: PA1) [3]
Mitomycin + Ridaforolimus DC6CJSL Mitomycin Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Mitomycin + Ridaforolimus DC7JUBY Mitomycin Malignant melanoma (Cell Line: A375) [3]
Mitomycin + Ridaforolimus DCDVWKF Mitomycin Malignant melanoma (Cell Line: UACC62) [3]
Mitomycin + Ridaforolimus DC2IZB4 Mitomycin Mesothelioma (Cell Line: MSTO) [3]
Mitomycin + Ridaforolimus DCF9C0D Mitomycin Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Mitomycin + Ridaforolimus DCKSNEG Mitomycin Prostate carcinoma (Cell Line: VCAP) [3]
Mitomycin + Ridaforolimus DCH60UY Mitomycin Prostate carcinoma (Cell Line: LNCAP) [3]
MK-1775 + Ridaforolimus DCT7IN2 MK-1775 Adenocarcinoma (Cell Line: CAOV3) [4]
MK-1775 + Ridaforolimus DCS8YOH MK-1775 Adenocarcinoma (Cell Line: NCIH2122) [4]
MK-1775 + Ridaforolimus DC52I6V MK-1775 Adenocarcinoma (Cell Line: HCT116) [4]
MK-1775 + Ridaforolimus DCU728B MK-1775 Adenocarcinoma (Cell Line: HT29) [4]
MK-1775 + Ridaforolimus DCFRRQC MK-1775 Amelanotic melanoma (Cell Line: A2058) [4]
MK-1775 + Ridaforolimus DCJXCKO MK-1775 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
MK-1775 + Ridaforolimus DCMVRXJ MK-1775 Germ cell tumour (Cell Line: PA1) [4]
MK-1775 + Ridaforolimus DCGA5J7 MK-1775 Malignant melanoma (Cell Line: A375) [4]
MK-1775 + Ridaforolimus DCPG0HL MK-1775 Malignant melanoma (Cell Line: SKMEL30) [4]
MK-1775 + Ridaforolimus DCZRS2V MK-1775 Mesothelioma (Cell Line: MSTO) [4]
MK-1775 + Ridaforolimus DCMF756 MK-1775 Non small cell carcinoma (Cell Line: SKMES1) [4]
MK-1775 + Ridaforolimus DC5YV74 MK-1775 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-1775 + Ridaforolimus DCX10HL MK-1775 Prostate carcinoma (Cell Line: LNCAP) [4]
MK-1775 + Ridaforolimus DCOSCKI MK-1775 Prostate carcinoma (Cell Line: VCAP) [4]
MK-1775 + Ridaforolimus DC0IBEJ MK-1775 Breast carcinoma (Cell Line: KPL1) [2]
MK-1775 + Ridaforolimus DCI0DOY MK-1775 Colon adenocarcinoma (Cell Line: LOVO) [2]
MK-1775 + Ridaforolimus DCYKCYG MK-1775 Colon carcinoma (Cell Line: RKO) [2]
MK-2206 + Ridaforolimus DC48CAC MK-2206 Adenocarcinoma (Cell Line: CAOV3) [4]
MK-2206 + Ridaforolimus DCZXKTY MK-2206 Adenocarcinoma (Cell Line: OVCAR3) [4]
MK-2206 + Ridaforolimus DCJZV07 MK-2206 Adenocarcinoma (Cell Line: NCIH1650) [4]
MK-2206 + Ridaforolimus DCJ7VZE MK-2206 Adenocarcinoma (Cell Line: NCIH2122) [4]
MK-2206 + Ridaforolimus DCLXPYZ MK-2206 Adenocarcinoma (Cell Line: COLO320DM) [4]
MK-2206 + Ridaforolimus DCYDYVJ MK-2206 Adenocarcinoma (Cell Line: HT29) [4]
MK-2206 + Ridaforolimus DCC0HE3 MK-2206 Amelanotic melanoma (Cell Line: A2058) [4]
MK-2206 + Ridaforolimus DCIY1D4 MK-2206 Germ cell tumour (Cell Line: PA1) [4]
MK-2206 + Ridaforolimus DCRYW61 MK-2206 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
MK-2206 + Ridaforolimus DCP7TU8 MK-2206 Mesothelioma (Cell Line: MSTO) [4]
MK-2206 + Ridaforolimus DC29IMA MK-2206 Non small cell carcinoma (Cell Line: SKMES1) [4]
MK-2206 + Ridaforolimus DCMI7EV MK-2206 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
MK-2206 + Ridaforolimus DCI7PGA MK-2206 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
MK-2206 + Ridaforolimus DCAXGLU MK-2206 Prostate carcinoma (Cell Line: LNCAP) [4]
MK-2206 + Ridaforolimus DC6WQZ4 MK-2206 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [2]
MK-2206 + Ridaforolimus DCQUG4C MK-2206 Breast carcinoma (Cell Line: KPL1) [2]
MK-2206 + Ridaforolimus DC9Q5VX MK-2206 Carcinoma (Cell Line: MDAMB436) [2]
MK-2206 + Ridaforolimus DCOEZ7I MK-2206 Invasive ductal carcinoma (Cell Line: T-47D) [2]
MK-4827 + Ridaforolimus DCFE32M MK-4827 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
MK-4827 + Ridaforolimus DCZDKU8 MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [2]
MK-4827 + Ridaforolimus DCPRVAD MK-4827 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
MK-4827 + Ridaforolimus DCDUHPX MK-4827 Breast carcinoma (Cell Line: ZR751) [2]
MK-4827 + Ridaforolimus DCWNYY8 MK-4827 Breast carcinoma (Cell Line: KPL1) [2]
MK-4827 + Ridaforolimus DCD43IB MK-4827 Breast carcinoma (Cell Line: OCUBM) [2]
MK-4827 + Ridaforolimus DCCLN9V MK-4827 Carcinoma (Cell Line: OV90) [2]
MK-4827 + Ridaforolimus DCCLJF5 MK-4827 Carcinoma (Cell Line: EFM192B) [2]
MK-4827 + Ridaforolimus DCGQXQR MK-4827 Carcinoma (Cell Line: MDAMB436) [2]
MK-4827 + Ridaforolimus DC4ZUBL MK-4827 Colon carcinoma (Cell Line: RKO) [2]
MK-4827 + Ridaforolimus DC42T8R MK-4827 Invasive ductal carcinoma (Cell Line: T-47D) [2]
MK-4827 + Ridaforolimus DCBPG0V MK-4827 Rectal adenocarcinoma (Cell Line: SW837) [2]
MK-4827 + Ridaforolimus DC64MA2 MK-4827 Adenocarcinoma (Cell Line: CAOV3) [3]
MK-4827 + Ridaforolimus DCNPSKT MK-4827 Adenocarcinoma (Cell Line: OVCAR3) [3]
MK-4827 + Ridaforolimus DCFVPZL MK-4827 Adenocarcinoma (Cell Line: NCIH1650) [3]
MK-4827 + Ridaforolimus DCI85EV MK-4827 Adenocarcinoma (Cell Line: NCIH2122) [3]
MK-4827 + Ridaforolimus DCTKCSW MK-4827 Adenocarcinoma (Cell Line: NCIH23) [3]
MK-4827 + Ridaforolimus DCW6IX0 MK-4827 Adenocarcinoma (Cell Line: COLO320DM) [3]
MK-4827 + Ridaforolimus DCZX6WL MK-4827 Adenocarcinoma (Cell Line: DLD1) [3]
MK-4827 + Ridaforolimus DCKF7RE MK-4827 Amelanotic melanoma (Cell Line: A2058) [3]
MK-4827 + Ridaforolimus DCFFX4H MK-4827 Germ cell tumour (Cell Line: PA1) [3]
MK-4827 + Ridaforolimus DC05ILJ MK-4827 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
MK-4827 + Ridaforolimus DCYI9EL MK-4827 Malignant melanoma (Cell Line: A375) [3]
MK-4827 + Ridaforolimus DCHL0Z9 MK-4827 Malignant melanoma (Cell Line: RPMI7951) [3]
MK-4827 + Ridaforolimus DCSZLAH MK-4827 Malignant melanoma (Cell Line: SKMEL30) [3]
MK-4827 + Ridaforolimus DCZ89NM MK-4827 Malignant melanoma (Cell Line: UACC62) [3]
MK-4827 + Ridaforolimus DCLTYOX MK-4827 Mesothelioma (Cell Line: MSTO) [3]
MK-4827 + Ridaforolimus DC02439 MK-4827 Non small cell carcinoma (Cell Line: SKMES1) [3]
MK-4827 + Ridaforolimus DCXZMTP MK-4827 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
MK-4827 + Ridaforolimus DCXQHDR MK-4827 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
MK-4827 + Ridaforolimus DCRW6IB MK-4827 Prostate carcinoma (Cell Line: LNCAP) [3]
MK-5108 + Ridaforolimus DCC9PAX MK-5108 Colon adenocarcinoma (Cell Line: LOVO) [2]
PD-0325901 + Ridaforolimus DC43W7M PD-0325901 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
PD-0325901 + Ridaforolimus DCDDROZ PD-0325901 Breast carcinoma (Cell Line: KPL1) [2]
PD-0325901 + Ridaforolimus DC0360N PD-0325901 Breast carcinoma (Cell Line: OCUBM) [2]
PD-0325901 + Ridaforolimus DCKRH4A PD-0325901 Colon carcinoma (Cell Line: RKO) [2]
PD-0325901 + Ridaforolimus DCP4H5P PD-0325901 Invasive ductal carcinoma (Cell Line: T-47D) [2]
PD-0325901 + Ridaforolimus DC7PT5Z PD-0325901 Rectal adenocarcinoma (Cell Line: SW837) [2]
PD-0325901 + Ridaforolimus DCEVYM5 PD-0325901 Adenocarcinoma (Cell Line: CAOV3) [3]
PD-0325901 + Ridaforolimus DC8N5SP PD-0325901 Adenocarcinoma (Cell Line: NCIH2122) [3]
PD-0325901 + Ridaforolimus DC3PBHC PD-0325901 Adenocarcinoma (Cell Line: NCIH23) [3]
PD-0325901 + Ridaforolimus DCHZ8B1 PD-0325901 Adenocarcinoma (Cell Line: COLO320DM) [3]
PD-0325901 + Ridaforolimus DCM046F PD-0325901 Adenocarcinoma (Cell Line: DLD1) [3]
PD-0325901 + Ridaforolimus DC68T45 PD-0325901 Adenocarcinoma (Cell Line: HT29) [3]
PD-0325901 + Ridaforolimus DC7DLDF PD-0325901 Amelanotic melanoma (Cell Line: A2058) [3]
PD-0325901 + Ridaforolimus DC1OJAA PD-0325901 Germ cell tumour (Cell Line: PA1) [3]
PD-0325901 + Ridaforolimus DC3PYGS PD-0325901 Malignant melanoma (Cell Line: A375) [3]
PD-0325901 + Ridaforolimus DCOKIS0 PD-0325901 Malignant melanoma (Cell Line: HT144) [3]
PD-0325901 + Ridaforolimus DC8HXZC PD-0325901 Mesothelioma (Cell Line: MSTO) [3]
PD-0325901 + Ridaforolimus DCKYXD2 PD-0325901 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
PD-0325901 + Ridaforolimus DCXDY12 PD-0325901 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
PD-0325901 + Ridaforolimus DC4AWUB PD-0325901 Prostate carcinoma (Cell Line: LNCAP) [3]
PMID28460551-Compound-2 + Ridaforolimus DCH8ERN PMID28460551-Compound-2 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [2]
PMID28460551-Compound-2 + Ridaforolimus DC3GBHK PMID28460551-Compound-2 Rectal adenocarcinoma (Cell Line: SW837) [2]
PMID28460551-Compound-2 + Ridaforolimus DCNS3HY PMID28460551-Compound-2 Adenocarcinoma (Cell Line: COLO320DM) [3]
PMID28460551-Compound-2 + Ridaforolimus DCCNT58 PMID28460551-Compound-2 Malignant melanoma (Cell Line: RPMI7951) [3]
PMID28460551-Compound-2 + Ridaforolimus DCUFY41 PMID28460551-Compound-2 Mesothelioma (Cell Line: MSTO) [3]
PMID28460551-Compound-2 + Ridaforolimus DCOE9PV PMID28460551-Compound-2 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
PMID28460551-Compound-2 + Ridaforolimus DCIAE4B PMID28460551-Compound-2 Prostate carcinoma (Cell Line: LNCAP) [3]
Pyrazinamide + Ridaforolimus DCJWIP3 Pyrazinamide Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Ridaforolimus + Alvespimycin hydrochloride DC7LKWQ Alvespimycin hydrochloride Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Ridaforolimus + Marizomib DC7IK4Q Marizomib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Ridaforolimus + Vincristine DC2VYN8 Vincristine Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Ridaforolimus + Dasatinib DCOE2EY Dasatinib Diffuse intrinsic pontine glioma (Cell Line: DIPG25) [4]
Ridaforolimus + SCH-900776 DCWZ7WW SCH-900776 Colon carcinoma (Cell Line: RKO) [2]
Ridaforolimus + SCH-900776 DCESKXL SCH-900776 Rectal adenocarcinoma (Cell Line: SW837) [2]
Ridaforolimus + SCH-900776 DCK3IF8 SCH-900776 Adenocarcinoma (Cell Line: COLO320DM) [3]
Ridaforolimus + SCH-900776 DCPML0E SCH-900776 Adenocarcinoma (Cell Line: HCT116) [3]
Ridaforolimus + SCH-900776 DC6TMI8 SCH-900776 Germ cell tumour (Cell Line: PA1) [3]
Ridaforolimus + SCH-900776 DCRR8RL SCH-900776 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Ridaforolimus + SCH-900776 DCUABO8 SCH-900776 Malignant melanoma (Cell Line: A375) [3]
Ridaforolimus + SCH-900776 DCFM6EN SCH-900776 Malignant melanoma (Cell Line: RPMI7951) [3]
Ridaforolimus + SCH-900776 DCZZMXP SCH-900776 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Ridaforolimus + SCH-900776 DCZOY5B SCH-900776 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
RTB101 + Ridaforolimus DCG1N85 RTB101 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
RTB101 + Ridaforolimus DCDS03D RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [2]
RTB101 + Ridaforolimus DCXFJ3A RTB101 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
RTB101 + Ridaforolimus DCLQE0M RTB101 Breast carcinoma (Cell Line: KPL1) [2]
RTB101 + Ridaforolimus DCL12U8 RTB101 Breast carcinoma (Cell Line: OCUBM) [2]
RTB101 + Ridaforolimus DCVCHPB RTB101 Carcinoma (Cell Line: OV90) [2]
RTB101 + Ridaforolimus DC42M44 RTB101 Carcinoma (Cell Line: EFM192B) [2]
RTB101 + Ridaforolimus DCSMB49 RTB101 Carcinoma (Cell Line: MDAMB436) [2]
RTB101 + Ridaforolimus DC32D75 RTB101 Colon adenocarcinoma (Cell Line: LOVO) [2]
RTB101 + Ridaforolimus DCON33B RTB101 Colon carcinoma (Cell Line: RKO) [2]
RTB101 + Ridaforolimus DCQBGAY RTB101 Invasive ductal carcinoma (Cell Line: T-47D) [2]
RTB101 + Ridaforolimus DCB3AZD RTB101 Rectal adenocarcinoma (Cell Line: SW837) [2]
RTB101 + Ridaforolimus DCDAC43 RTB101 Adenocarcinoma (Cell Line: CAOV3) [3]
RTB101 + Ridaforolimus DCWQ8GD RTB101 Adenocarcinoma (Cell Line: OVCAR3) [3]
RTB101 + Ridaforolimus DCNN60Y RTB101 Adenocarcinoma (Cell Line: A427) [3]
RTB101 + Ridaforolimus DC633J4 RTB101 Adenocarcinoma (Cell Line: NCIH1650) [3]
RTB101 + Ridaforolimus DCK1RN6 RTB101 Adenocarcinoma (Cell Line: NCIH2122) [3]
RTB101 + Ridaforolimus DC11JDJ RTB101 Adenocarcinoma (Cell Line: NCIH23) [3]
RTB101 + Ridaforolimus DC2FP5T RTB101 Adenocarcinoma (Cell Line: NCIH520) [3]
RTB101 + Ridaforolimus DCAAG7Z RTB101 Adenocarcinoma (Cell Line: COLO320DM) [3]
RTB101 + Ridaforolimus DCYA1NH RTB101 Adenocarcinoma (Cell Line: DLD1) [3]
RTB101 + Ridaforolimus DC1JPKC RTB101 Adenocarcinoma (Cell Line: HT29) [3]
RTB101 + Ridaforolimus DCI3XU5 RTB101 Adenocarcinoma (Cell Line: SW-620) [3]
RTB101 + Ridaforolimus DCVFEF2 RTB101 Amelanotic melanoma (Cell Line: A2058) [3]
RTB101 + Ridaforolimus DC6B4WV RTB101 Germ cell tumour (Cell Line: PA1) [3]
RTB101 + Ridaforolimus DCVYWZH RTB101 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
RTB101 + Ridaforolimus DCP24AP RTB101 Malignant melanoma (Cell Line: A375) [3]
RTB101 + Ridaforolimus DCWP25P RTB101 Malignant melanoma (Cell Line: HT144) [3]
RTB101 + Ridaforolimus DC7KTTZ RTB101 Malignant melanoma (Cell Line: RPMI7951) [3]
RTB101 + Ridaforolimus DCJH8R6 RTB101 Malignant melanoma (Cell Line: SKMEL30) [3]
RTB101 + Ridaforolimus DCGTM6F RTB101 Malignant melanoma (Cell Line: UACC62) [3]
RTB101 + Ridaforolimus DCPKBCI RTB101 Mesothelioma (Cell Line: MSTO) [3]
RTB101 + Ridaforolimus DCH0RMP RTB101 Non small cell carcinoma (Cell Line: SKMES1) [3]
RTB101 + Ridaforolimus DC6P8BI RTB101 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
RTB101 + Ridaforolimus DCUA4QR RTB101 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
RTB101 + Ridaforolimus DC1AMWS RTB101 Prostate carcinoma (Cell Line: VCAP) [3]
RTB101 + Ridaforolimus DCD3KOO RTB101 Prostate carcinoma (Cell Line: LNCAP) [3]
SCH 727965 + Ridaforolimus DC0BICP SCH 727965 Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
SCH 727965 + Ridaforolimus DCQ2OYW SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289) [2]
SCH 727965 + Ridaforolimus DC72FKC SCH 727965 Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
SCH 727965 + Ridaforolimus DCNDLIW SCH 727965 Breast carcinoma (Cell Line: KPL1) [2]
SCH 727965 + Ridaforolimus DCGKR47 SCH 727965 Breast carcinoma (Cell Line: OCUBM) [2]
SCH 727965 + Ridaforolimus DCXC8ZA SCH 727965 Carcinoma (Cell Line: EFM192B) [2]
SCH 727965 + Ridaforolimus DCFEANK SCH 727965 Carcinoma (Cell Line: MDAMB436) [2]
SCH 727965 + Ridaforolimus DCH9K1D SCH 727965 Colon adenocarcinoma (Cell Line: LOVO) [2]
SCH 727965 + Ridaforolimus DC14K0D SCH 727965 Colon carcinoma (Cell Line: RKO) [2]
SCH 727965 + Ridaforolimus DCGD6X4 SCH 727965 Rectal adenocarcinoma (Cell Line: SW837) [2]
SCH 727965 + Ridaforolimus DCDEMPY SCH 727965 Adenocarcinoma (Cell Line: CAOV3) [3]
SCH 727965 + Ridaforolimus DCMTW0E SCH 727965 Adenocarcinoma (Cell Line: A427) [3]
SCH 727965 + Ridaforolimus DCIKHF6 SCH 727965 Adenocarcinoma (Cell Line: NCIH1650) [3]
SCH 727965 + Ridaforolimus DCMK9Y9 SCH 727965 Adenocarcinoma (Cell Line: NCIH23) [3]
SCH 727965 + Ridaforolimus DCP8IOP SCH 727965 Adenocarcinoma (Cell Line: NCIH520) [3]
SCH 727965 + Ridaforolimus DCYFQOS SCH 727965 Adenocarcinoma (Cell Line: COLO320DM) [3]
SCH 727965 + Ridaforolimus DC9K291 SCH 727965 Adenocarcinoma (Cell Line: HT29) [3]
SCH 727965 + Ridaforolimus DCZTKNF SCH 727965 Adenocarcinoma (Cell Line: SW-620) [3]
SCH 727965 + Ridaforolimus DCHJI10 SCH 727965 Adenocarcinoma (Cell Line: HCT116) [3]
SCH 727965 + Ridaforolimus DC60NVT SCH 727965 Amelanotic melanoma (Cell Line: A2058) [3]
SCH 727965 + Ridaforolimus DCCFMW0 SCH 727965 Germ cell tumour (Cell Line: PA1) [3]
SCH 727965 + Ridaforolimus DCAPBAE SCH 727965 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
SCH 727965 + Ridaforolimus DCRS76M SCH 727965 Malignant melanoma (Cell Line: A375) [3]
SCH 727965 + Ridaforolimus DC916VH SCH 727965 Malignant melanoma (Cell Line: RPMI7951) [3]
SCH 727965 + Ridaforolimus DCXCA3V SCH 727965 Malignant melanoma (Cell Line: UACC62) [3]
SCH 727965 + Ridaforolimus DC6WQ7G SCH 727965 Mesothelioma (Cell Line: MSTO) [3]
SCH 727965 + Ridaforolimus DC0RRZX SCH 727965 Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
SCH 727965 + Ridaforolimus DCJMWA6 SCH 727965 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
SCH 727965 + Ridaforolimus DCPXSYD SCH 727965 Prostate carcinoma (Cell Line: LNCAP) [3]
SCH 727965 + Ridaforolimus DC3DXJR SCH 727965 Prostate carcinoma (Cell Line: VCAP) [3]
SNX-2112 + Ridaforolimus DCJCHWI SNX-2112 Carcinoma (Cell Line: EFM192B) [2]
SNX-2112 + Ridaforolimus DC2WE6M SNX-2112 Carcinoma (Cell Line: MDAMB436) [2]
SNX-2112 + Ridaforolimus DCS3TSH SNX-2112 Colon carcinoma (Cell Line: RKO) [2]
SNX-2112 + Ridaforolimus DCVBB2F SNX-2112 Invasive ductal carcinoma (Cell Line: T-47D) [2]
SNX-2112 + Ridaforolimus DCX1QTU SNX-2112 Adenocarcinoma (Cell Line: CAOV3) [3]
SNX-2112 + Ridaforolimus DCMTTD3 SNX-2112 Adenocarcinoma (Cell Line: NCIH2122) [3]
SNX-2112 + Ridaforolimus DCKXLSW SNX-2112 Adenocarcinoma (Cell Line: DLD1) [3]
SNX-2112 + Ridaforolimus DCWM032 SNX-2112 Adenocarcinoma (Cell Line: HCT116) [3]
SNX-2112 + Ridaforolimus DCYPS1H SNX-2112 Adenocarcinoma (Cell Line: SW-620) [3]
SNX-2112 + Ridaforolimus DCH19O2 SNX-2112 Amelanotic melanoma (Cell Line: A2058) [3]
SNX-2112 + Ridaforolimus DCM8Y2J SNX-2112 Germ cell tumour (Cell Line: PA1) [3]
SNX-2112 + Ridaforolimus DCT6FGM SNX-2112 Large cell lung carcinoma (Cell Line: NCI-H460) [3]
SNX-2112 + Ridaforolimus DC1NNPI SNX-2112 Malignant melanoma (Cell Line: A375) [3]
SNX-2112 + Ridaforolimus DCDSY16 SNX-2112 Malignant melanoma (Cell Line: HT144) [3]
SNX-2112 + Ridaforolimus DCXOV9U SNX-2112 Non small cell carcinoma (Cell Line: SKMES1) [3]
SNX-2112 + Ridaforolimus DCT7HLP SNX-2112 Prostate carcinoma (Cell Line: LNCAP) [3]
Sorafenib + Ridaforolimus DCRZFHB Sorafenib Adenocarcinoma (Cell Line: CAOV3) [4]
Sorafenib + Ridaforolimus DCUSMD8 Sorafenib Adenocarcinoma (Cell Line: A427) [4]
Sorafenib + Ridaforolimus DCTC7VP Sorafenib Adenocarcinoma (Cell Line: DLD1) [4]
Sorafenib + Ridaforolimus DCG5WD0 Sorafenib Adenocarcinoma (Cell Line: SW-620) [4]
Sorafenib + Ridaforolimus DCPVBPO Sorafenib Amelanotic melanoma (Cell Line: A2058) [4]
Sorafenib + Ridaforolimus DCBLHZW Sorafenib Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Sorafenib + Ridaforolimus DC9GBXS Sorafenib Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Sorafenib + Ridaforolimus DCBS4D2 Sorafenib Malignant melanoma (Cell Line: A375) [4]
Sorafenib + Ridaforolimus DC78PJK Sorafenib Malignant melanoma (Cell Line: HT144) [4]
Sorafenib + Ridaforolimus DCP6H8I Sorafenib Malignant melanoma (Cell Line: SKMEL30) [4]
Sorafenib + Ridaforolimus DCSBPF8 Sorafenib Malignant melanoma (Cell Line: UACC62) [4]
Sorafenib + Ridaforolimus DCOW676 Sorafenib Mesothelioma (Cell Line: MSTO) [4]
Sorafenib + Ridaforolimus DCS3ZW4 Sorafenib Non small cell carcinoma (Cell Line: SKMES1) [4]
Sorafenib + Ridaforolimus DCB1JHR Sorafenib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Sorafenib + Ridaforolimus DC1NRHB Sorafenib Breast and ovarian cancer syndrome (Cell Line: UWB1289) [2]
Sorafenib + Ridaforolimus DCRP8UX Sorafenib Breast carcinoma (Cell Line: OCUBM) [2]
Sorafenib + Ridaforolimus DCQR502 Sorafenib Carcinoma (Cell Line: OV90) [2]
Sorafenib + Ridaforolimus DC45XJ5 Sorafenib Colon carcinoma (Cell Line: RKO) [2]
Sorafenib + Ridaforolimus DC371OS Sorafenib Invasive ductal carcinoma (Cell Line: T-47D) [2]
Taxol + Ridaforolimus DCY50IV Taxol Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Taxol + Ridaforolimus DCXI2FY Taxol Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
Taxol + Ridaforolimus DCP02CS Taxol Carcinoma (Cell Line: OV90) [2]
Taxol + Ridaforolimus DC54L7L Taxol Carcinoma (Cell Line: EFM192B) [2]
Taxol + Ridaforolimus DCSWG7D Taxol Carcinoma (Cell Line: MDAMB436) [2]
Taxol + Ridaforolimus DCTHKEL Taxol Colon carcinoma (Cell Line: RKO) [2]
Taxol + Ridaforolimus DC6ICEC Taxol Rectal adenocarcinoma (Cell Line: SW837) [2]
Taxol + Ridaforolimus DCECDFA Taxol Adenocarcinoma (Cell Line: A427) [3]
Taxol + Ridaforolimus DCWKYC8 Taxol Adenocarcinoma (Cell Line: NCIH1650) [3]
Taxol + Ridaforolimus DCBII65 Taxol Adenocarcinoma (Cell Line: NCIH2122) [3]
Taxol + Ridaforolimus DCXXNHC Taxol Adenocarcinoma (Cell Line: NCIH520) [3]
Taxol + Ridaforolimus DCBIJMR Taxol Adenocarcinoma (Cell Line: DLD1) [3]
Taxol + Ridaforolimus DCSMZJ0 Taxol Adenocarcinoma (Cell Line: HCT116) [3]
Taxol + Ridaforolimus DCTGM32 Taxol Adenocarcinoma (Cell Line: HT29) [3]
Taxol + Ridaforolimus DCIUV69 Taxol Germ cell tumour (Cell Line: PA1) [3]
Taxol + Ridaforolimus DC86OV8 Taxol Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Taxol + Ridaforolimus DCIZ5AX Taxol Malignant melanoma (Cell Line: A375) [3]
Taxol + Ridaforolimus DCDVY4I Taxol Malignant melanoma (Cell Line: HT144) [3]
Taxol + Ridaforolimus DCD8I9I Taxol Malignant melanoma (Cell Line: RPMI7951) [3]
Taxol + Ridaforolimus DCZ3QDA Taxol Malignant melanoma (Cell Line: UACC62) [3]
Taxol + Ridaforolimus DCDK86V Taxol Mesothelioma (Cell Line: MSTO) [3]
Taxol + Ridaforolimus DC4HIA9 Taxol Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Taxol + Ridaforolimus DCAV1OH Taxol Prostate carcinoma (Cell Line: LNCAP) [3]
Taxol + Ridaforolimus DCA92X7 Taxol Prostate carcinoma (Cell Line: VCAP) [3]
Topotecan + Ridaforolimus DC0ZEKI Topotecan Breast and ovarian cancer syndrome (Cell Line: UWB1289) [2]
Topotecan + Ridaforolimus DCDYH3F Topotecan Carcinoma (Cell Line: EFM192B) [2]
Topotecan + Ridaforolimus DC7KLBQ Topotecan Colon carcinoma (Cell Line: RKO) [2]
Topotecan + Ridaforolimus DCWF4HD Topotecan Invasive ductal carcinoma (Cell Line: T-47D) [2]
Topotecan + Ridaforolimus DCGPGL1 Topotecan Adenocarcinoma (Cell Line: NCIH1650) [3]
Topotecan + Ridaforolimus DCMSXNH Topotecan Adenocarcinoma (Cell Line: NCIH2122) [3]
Topotecan + Ridaforolimus DCOP16M Topotecan Adenocarcinoma (Cell Line: NCIH23) [3]
Topotecan + Ridaforolimus DC06EGR Topotecan Adenocarcinoma (Cell Line: COLO320DM) [3]
Topotecan + Ridaforolimus DCUALSA Topotecan Adenocarcinoma (Cell Line: DLD1) [3]
Topotecan + Ridaforolimus DCBYXSE Topotecan Adenocarcinoma (Cell Line: HCT116) [3]
Topotecan + Ridaforolimus DC5MA5R Topotecan Adenocarcinoma (Cell Line: HT29) [3]
Topotecan + Ridaforolimus DCS449Y Topotecan Amelanotic melanoma (Cell Line: A2058) [3]
Topotecan + Ridaforolimus DCWE12J Topotecan Germ cell tumour (Cell Line: PA1) [3]
Topotecan + Ridaforolimus DCHHSG7 Topotecan Mesothelioma (Cell Line: MSTO) [3]
Topotecan + Ridaforolimus DCXOK60 Topotecan Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [3]
Topotecan + Ridaforolimus DCICO6J Topotecan Prostate carcinoma (Cell Line: LNCAP) [3]
Vinblastine + Ridaforolimus DCGLAEF Vinblastine Adenocarcinoma (Cell Line: CAOV3) [4]
Vinblastine + Ridaforolimus DCYHIWJ Vinblastine Adenocarcinoma (Cell Line: NCIH2122) [4]
Vinblastine + Ridaforolimus DCGPPW8 Vinblastine Malignant melanoma (Cell Line: RPMI7951) [4]
Vinblastine + Ridaforolimus DCPIFLS Vinblastine Malignant melanoma (Cell Line: UACC62) [4]
Vinblastine + Ridaforolimus DCIUUH7 Vinblastine Mesothelioma (Cell Line: MSTO) [4]
Vinblastine + Ridaforolimus DCZ58W3 Vinblastine Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Vinblastine + Ridaforolimus DCM6TTJ Vinblastine Prostate carcinoma (Cell Line: LNCAP) [4]
Vinblastine + Ridaforolimus DC96QWW Vinblastine Breast carcinoma (Cell Line: KPL1) [2]
Vinblastine + Ridaforolimus DCM6OIV Vinblastine Breast carcinoma (Cell Line: OCUBM) [2]
Vinblastine + Ridaforolimus DCEI53K Vinblastine Colon carcinoma (Cell Line: RKO) [2]
Vinblastine + Ridaforolimus DCWGPY1 Vinblastine Rectal adenocarcinoma (Cell Line: SW837) [2]
Vinorelbine + Ridaforolimus DCW6M2E Vinorelbine Breast and ovarian cancer syndrome (Cell Line: UWB1289) [2]
Vinorelbine + Ridaforolimus DCCKIZK Vinorelbine Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
Vinorelbine + Ridaforolimus DC6T56A Vinorelbine Breast carcinoma (Cell Line: ZR751) [2]
Vinorelbine + Ridaforolimus DCD4RGA Vinorelbine Carcinoma (Cell Line: OV90) [2]
Vinorelbine + Ridaforolimus DC9Z5AZ Vinorelbine Carcinoma (Cell Line: EFM192B) [2]
Vinorelbine + Ridaforolimus DCN47DC Vinorelbine Colon adenocarcinoma (Cell Line: LOVO) [2]
Vinorelbine + Ridaforolimus DCVQRLS Vinorelbine Colon carcinoma (Cell Line: RKO) [2]
Vinorelbine + Ridaforolimus DCCRYPP Vinorelbine Invasive ductal carcinoma (Cell Line: T-47D) [2]
Vinorelbine + Ridaforolimus DCMU92I Vinorelbine Rectal adenocarcinoma (Cell Line: SW837) [2]
Vinorelbine + Ridaforolimus DCHYD1R Vinorelbine Adenocarcinoma (Cell Line: CAOV3) [3]
Vinorelbine + Ridaforolimus DCWLRQN Vinorelbine Adenocarcinoma (Cell Line: OVCAR3) [3]
Vinorelbine + Ridaforolimus DCNHA7M Vinorelbine Adenocarcinoma (Cell Line: NCIH1650) [3]
Vinorelbine + Ridaforolimus DCRHGHO Vinorelbine Adenocarcinoma (Cell Line: NCIH2122) [3]
Vinorelbine + Ridaforolimus DCBLG82 Vinorelbine Adenocarcinoma (Cell Line: NCIH520) [3]
Vinorelbine + Ridaforolimus DCFKMUS Vinorelbine Adenocarcinoma (Cell Line: DLD1) [3]
Vinorelbine + Ridaforolimus DC6FRYG Vinorelbine Adenocarcinoma (Cell Line: SW-620) [3]
Vinorelbine + Ridaforolimus DCSN3PF Vinorelbine Amelanotic melanoma (Cell Line: A2058) [3]
Vinorelbine + Ridaforolimus DCD6DCI Vinorelbine Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [3]
Vinorelbine + Ridaforolimus DC5YA49 Vinorelbine Large cell lung carcinoma (Cell Line: NCI-H460) [3]
Vinorelbine + Ridaforolimus DCLJ3AV Vinorelbine Malignant melanoma (Cell Line: HT144) [3]
Vinorelbine + Ridaforolimus DC2UJTM Vinorelbine Malignant melanoma (Cell Line: RPMI7951) [3]
Vinorelbine + Ridaforolimus DCL7OAL Vinorelbine Malignant melanoma (Cell Line: SKMEL30) [3]
Vinorelbine + Ridaforolimus DCZ44U1 Vinorelbine Malignant melanoma (Cell Line: UACC62) [3]
Vinorelbine + Ridaforolimus DCI9GAS Vinorelbine Mesothelioma (Cell Line: MSTO) [3]
Vinorelbine + Ridaforolimus DCZ1Q71 Vinorelbine Non small cell carcinoma (Cell Line: SKMES1) [3]
Vinorelbine + Ridaforolimus DCP26M4 Vinorelbine Prostate carcinoma (Cell Line: LNCAP) [3]
Vorinostat + Ridaforolimus DCOOD1L Vorinostat Adenocarcinoma (Cell Line: CAOV3) [4]
Vorinostat + Ridaforolimus DCX32I8 Vorinostat Adenocarcinoma (Cell Line: NCIH2122) [4]
Vorinostat + Ridaforolimus DCQOVL7 Vorinostat Adenocarcinoma (Cell Line: NCIH520) [4]
Vorinostat + Ridaforolimus DCL0FQE Vorinostat Adenocarcinoma (Cell Line: DLD1) [4]
Vorinostat + Ridaforolimus DCOEWXJ Vorinostat Adenocarcinoma (Cell Line: HCT116) [4]
Vorinostat + Ridaforolimus DC6S4Q9 Vorinostat Amelanotic melanoma (Cell Line: A2058) [4]
Vorinostat + Ridaforolimus DCKAX17 Vorinostat Ewing sarcoma-peripheral primitive neuroectodermal tumour (Cell Line: ES2) [4]
Vorinostat + Ridaforolimus DC552QL Vorinostat Germ cell tumour (Cell Line: PA1) [4]
Vorinostat + Ridaforolimus DCQX0J6 Vorinostat Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Vorinostat + Ridaforolimus DC11BUH Vorinostat Malignant melanoma (Cell Line: A375) [4]
Vorinostat + Ridaforolimus DCC79U2 Vorinostat Malignant melanoma (Cell Line: HT144) [4]
Vorinostat + Ridaforolimus DCFDTTV Vorinostat Malignant melanoma (Cell Line: RPMI7951) [4]
Vorinostat + Ridaforolimus DC3L5CB Vorinostat Malignant melanoma (Cell Line: UACC62) [4]
Vorinostat + Ridaforolimus DCNAYYU Vorinostat Mesothelioma (Cell Line: MSTO) [4]
Vorinostat + Ridaforolimus DC3TSDM Vorinostat Ovarian endometrioid adenocarcinoma (Cell Line: A2780) [4]
Vorinostat + Ridaforolimus DC545GZ Vorinostat Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Vorinostat + Ridaforolimus DCQFE2D Vorinostat Prostate carcinoma (Cell Line: VCAP) [4]
Vorinostat + Ridaforolimus DC076PV Vorinostat Breast and ovarian cancer syndrome (Cell Line: UWB1289+BRCA1) [2]
Vorinostat + Ridaforolimus DCHG02S Vorinostat Breast carcinoma (Cell Line: KPL1) [2]
Vorinostat + Ridaforolimus DCNG9WV Vorinostat Colon adenocarcinoma (Cell Line: LOVO) [2]
Vorinostat + Ridaforolimus DCK6GAX Vorinostat Colon carcinoma (Cell Line: RKO) [2]
Vorinostat + Ridaforolimus DCNXBZX Vorinostat Invasive ductal carcinoma (Cell Line: T-47D) [2]
Vorinostat + Ridaforolimus DC2HYD7 Vorinostat Rectal adenocarcinoma (Cell Line: SW837) [2]
------------------------------------------------------------------------------------
⏷ Show the Full List of 556 DrugCom(s)
3 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Exemestane + Ridaforolimus DCRJMFI Exemestane Breast Neoplasms [5]
Ridaforolimus + Vorinostat DCL3CEH Vorinostat Lymphoma [6]
Ridaforolimus + Midazolam DCLOX37 Midazolam Relapsed or Refractory Advanced Cancer [7]
------------------------------------------------------------------------------------

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7884).
2 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
3 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 ClinicalTrials.gov (NCT01605396) A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064). U.S. National Institutes of Health.
6 ClinicalTrials.gov (NCT01169532) Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma
7 ClinicalTrials.gov (NCT01071304) Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)